BR112017005266A2 - inibidores de mk2 e uso dos mesmos - Google Patents

inibidores de mk2 e uso dos mesmos

Info

Publication number
BR112017005266A2
BR112017005266A2 BR112017005266A BR112017005266A BR112017005266A2 BR 112017005266 A2 BR112017005266 A2 BR 112017005266A2 BR 112017005266 A BR112017005266 A BR 112017005266A BR 112017005266 A BR112017005266 A BR 112017005266A BR 112017005266 A2 BR112017005266 A2 BR 112017005266A2
Authority
BR
Brazil
Prior art keywords
inhibitors
compositions
compounds
methods
relates
Prior art date
Application number
BR112017005266A
Other languages
English (en)
Other versions
BR112017005266B1 (pt
Inventor
Pabba Chittari
Chuaqui Claudio
Niu Deqiang
MALONA John
John Mcdonald Joseph
Singh Juswinder
david alexander Matthew
C Petter Russell
Ni Yike
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of BR112017005266A2 publication Critical patent/BR112017005266A2/pt
Publication of BR112017005266B1 publication Critical patent/BR112017005266B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

a presente invenção refere-se a compostos, composições dos mesmos, e métodos de uso dos mesmos.
BR112017005266-0A 2014-09-17 2015-09-16 Compostos inibidores de mk2 e composição farmaceuticamente aceitável que os compreende BR112017005266B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
BR112017005266A2 true BR112017005266A2 (pt) 2017-12-12
BR112017005266B1 BR112017005266B1 (pt) 2022-11-01

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005266-0A BR112017005266B1 (pt) 2014-09-17 2015-09-16 Compostos inibidores de mk2 e composição farmaceuticamente aceitável que os compreende

Country Status (29)

Country Link
US (5) US9458175B2 (pt)
EP (2) EP3912981A1 (pt)
JP (3) JP6556225B2 (pt)
KR (1) KR102457848B1 (pt)
CN (1) CN106998692B (pt)
AU (1) AU2015317741B2 (pt)
BR (1) BR112017005266B1 (pt)
CA (1) CA2961607C (pt)
CL (1) CL2017000576A1 (pt)
CO (1) CO2017003279A2 (pt)
CY (1) CY1124215T1 (pt)
DK (1) DK3193611T3 (pt)
EA (1) EA037299B1 (pt)
EC (1) ECSP17023281A (pt)
ES (1) ES2874561T3 (pt)
HR (1) HRP20210529T1 (pt)
HU (1) HUE054347T2 (pt)
IL (1) IL251051B (pt)
LT (1) LT3193611T (pt)
MA (1) MA40534B1 (pt)
MX (2) MX2017003359A (pt)
PL (1) PL3193611T3 (pt)
PT (1) PT3193611T (pt)
RS (1) RS62017B1 (pt)
SA (1) SA517381115B1 (pt)
SG (2) SG10201902326XA (pt)
SI (1) SI3193611T1 (pt)
TW (1) TWI744217B (pt)
WO (1) WO2016044463A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
JP6556225B2 (ja) 2014-09-17 2019-08-07 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤およびその使用
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
WO2018170204A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
WO2018170200A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
MX2019010643A (es) * 2017-03-16 2019-10-17 Celgene Car Llc Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
MX2019010642A (es) 2017-03-16 2019-10-17 Celgene Car Llc Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
WO2018170201A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
CN114364681A (zh) * 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
KR20220154094A (ko) * 2020-02-14 2022-11-21 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ulk1/2 억제제를 이용한 단일 및 병용 요법
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
US20230255979A1 (en) * 2020-07-24 2023-08-17 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
KR20230142529A (ko) 2021-02-01 2023-10-11 셀진 코포레이션 Mk2 억제제, 이의 합성, 및 이의 중간체
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
CN117940433A (zh) * 2021-08-27 2024-04-26 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
MX2024008704A (es) 2022-01-14 2024-07-22 Shanghai Hansoh Biomedical Co Ltd Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
US20240190890A1 (en) * 2022-10-27 2024-06-13 Bristol-Myers Squibb Company Mk2 inhibitors and uses thereof
WO2024167950A1 (en) * 2023-02-07 2024-08-15 Celgene Corporation Compounds and compositions useful as degraders of mk2 kinase

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1572682A4 (en) 2002-12-20 2008-01-23 Pharmacia Corp ACYCLIC PYRAZOLE COMPOUNDS
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
MX2007009388A (es) 2005-02-04 2007-09-25 Senomyx Inc Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles.
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0814426A2 (pt) 2007-07-16 2015-01-06 Novartis Ag Compostos heterocíclicos úteis como inibidores de mk2
EP2217596B8 (en) 2007-10-22 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
JP2011526299A (ja) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
ES2742261T3 (es) * 2011-04-15 2020-02-13 Hivih Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos
CN104136576B (zh) 2012-02-22 2020-10-16 默克专利股份有限公司 液晶介质
US9187453B2 (en) * 2012-03-28 2015-11-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
WO2014011902A1 (en) * 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9760590B2 (en) * 2012-09-24 2017-09-12 Claremont Speede Mobile sender controlled data access and data deletion method and system
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
JP6556225B2 (ja) 2014-09-17 2019-08-07 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤およびその使用
BR112017014737A2 (pt) 2015-01-08 2018-01-16 Moerae Matrix Inc formulação de peptídeos inibidores de mk2
WO2018170201A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Deuterated analogs of mk2 inhibitors and uses thereof
MX2019010643A (es) 2017-03-16 2019-10-17 Celgene Car Llc Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
MX2019010642A (es) 2017-03-16 2019-10-17 Celgene Car Llc Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
WO2018170204A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
CN114364681A (zh) 2019-05-17 2022-04-15 西建卡尔有限责任公司 治疗mk2介导的病症的方法
US20230255979A1 (en) 2020-07-24 2023-08-17 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders

Also Published As

Publication number Publication date
NZ730603A (en) 2024-02-23
ECSP17023281A (es) 2017-06-30
CA2961607A1 (en) 2016-03-24
HUE054347T2 (hu) 2021-08-30
PT3193611T (pt) 2021-05-28
AU2015317741B2 (en) 2020-01-16
US20170114073A1 (en) 2017-04-27
SG10201902326XA (en) 2019-04-29
US10253040B1 (en) 2019-04-09
DK3193611T3 (da) 2021-05-10
SG11201701861RA (en) 2017-04-27
CY1124215T1 (el) 2022-05-27
IL251051A0 (en) 2017-04-30
JP6556225B2 (ja) 2019-08-07
WO2016044463A2 (en) 2016-03-24
CO2017003279A2 (es) 2017-09-29
TW201617351A (zh) 2016-05-16
EP3912981A1 (en) 2021-11-24
EP3193611A4 (en) 2018-02-28
JP2019194236A (ja) 2019-11-07
BR112017005266B1 (pt) 2022-11-01
AU2015317741A1 (en) 2017-04-20
PL3193611T3 (pl) 2021-10-04
IL251051B (en) 2019-11-28
MX2020005213A (es) 2020-08-20
WO2016044463A3 (en) 2016-09-01
CL2017000576A1 (es) 2017-12-01
LT3193611T (lt) 2021-08-25
SI3193611T1 (sl) 2021-08-31
EP3193611B1 (en) 2021-03-24
MA40534B1 (fr) 2021-04-30
US20190375762A1 (en) 2019-12-12
JP2017529367A (ja) 2017-10-05
HRP20210529T1 (hr) 2021-08-06
EA201790380A1 (ru) 2017-08-31
US11584757B2 (en) 2023-02-21
EP3193611A2 (en) 2017-07-26
US10577380B2 (en) 2020-03-03
US9458175B2 (en) 2016-10-04
MA40534A (fr) 2016-03-24
SA517381115B1 (ar) 2021-03-09
MX2017003359A (es) 2017-11-22
RS62017B1 (sr) 2021-07-30
JP2022078315A (ja) 2022-05-24
CA2961607C (en) 2023-03-28
US9790235B2 (en) 2017-10-17
KR20170063734A (ko) 2017-06-08
EA037299B1 (ru) 2021-03-05
KR102457848B1 (ko) 2022-10-25
CN106998692B (zh) 2020-09-08
TWI744217B (zh) 2021-11-01
US20210053984A1 (en) 2021-02-25
CN106998692A (zh) 2017-08-01
US20160075720A1 (en) 2016-03-17
ES2874561T3 (es) 2021-11-05
JP7375072B2 (ja) 2023-11-07

Similar Documents

Publication Publication Date Title
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DK3542812T3 (da) Glycopeptidsammensætninger
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018011633A2 (pt) inibidores de aza-benzimidazol de pad4
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3240767T3 (da) Mikroindkapslede nitrifikationshæmmersammensætninger
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
DK3137437T3 (da) Mikroindkapslet nitrifikationsinhibitorsammensætning
DK3331498T3 (da) Nasalsammensætning
TR201820050T4 (tr) Bromodomain inhibitörleri olarak tetrahidrokinolin türevleri.
BR112017008867A2 (pt) inibidores de proteína quinases
EA201691493A1 (ru) Замещенные n-арилпиридиноны
DK3200827T3 (da) Sammensætninger
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
FR3046029B1 (fr) Composition fertilisante

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 57/00

Ipc: C07D 495/14 (2006.01), A61K 31/551 (2006.01), A61P

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/09/2015, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: BRISTOL-MYERS SQUIBB COMPANY (US)